IN THE NEWS
-
INTEGRAGEN ANNOUNCES AN AGREEMENT WITH A LEADING US CANCER CENTER FOR THE USE OF MERCURY™, THE ONCOLOGY SEQUENCING DATA INTERPRETATION AND REPORTING TOOL
IntegraGen announced today that the Dana Farber Cancer Institute will use MERCURYTM, IntegraGen's proprietary software, in their analysis and reporting of tumor sequencing data... Read More
-
COVID-19: MEASURES TO PROTECT EVERYONE AND ENSURE YOUR PROJECTS RUN SMOOTHLY
Dear IntegraGen customers and partners, We care about your satisfaction and understand that the entire community is impacted by COVID-19. That's why we're working hard to maintain... Read More
-
INTEGRAGEN RENEWS PARTNERSHIP AGREEMENT WITH INSTITUT PASTEUR FOR HIGH THROUGHPUT SEQUENCING IN MICROBIOLOGY
IntegraGen today announced the renewal, until December 2021, of its partnership agreement with the Institut Pasteur relating to high throughput sequencing operations for microbiology activities carried out... Read More
LATEST NEWS
-
INTEGRAGEN PARTICIPATES IN THE ASCO 2018 AMERICAN CANCER CONGRESS HELD IN CHICAGO FROM JUNE 1 TO 5
The annual ASCO meeting brings together more than 32,000 cancer specialists from around the world to... Read More
-
PUBLICATION IN BIOMARKER INSIGHTS OF TECHNICAL VALIDATION DATA FOR THE MIR-31-3P TEST
IntegraGen is pleased to announce that a full summary of the results of the validation studies for... Read More
-
INTEGRAGEN: A STRUCTURING DOUBLE AGREEMENT WITH TWIST BIOSCIENCE - INTERVIEW WITH BERNARD COURTIEU IN BIOTECH FINANCE
Bernard Courtieu answers questions from Pierre-Louis Germain, "Biotech Finance" specialist journalist, about the... Read More
-
PRESENTATION OF NEW RESULTS ON THE MIR-31-3P BIOMARKER IN AN ORAL PRESENTATION AT THE ESMO 2016 CONGRESS IN COPENHAGEN
The results of new analyses carried out on the FIRE-3 trial on the predictive role of the marker... Read More
